Lord CJ - Search Results

1

ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer.

Miller RE, Leary A, Scott CL, Serra V, Lord CJ, Bowtell D, Chang DK, Garsed DW, Jonkers J, Ledermann JA, Nik-Zainal S, Ray-Coquard I, Shah SP, Matias-Guiu X, Swisher EM, Yates LR. Miller RE, et al. Among authors: lord cj. Ann Oncol. 2020 Dec;31(12):1606-1622. doi: 10.1016/j.annonc.2020.08.2102. Epub 2020 Sep 28. Ann Oncol. 2020. PMID: 33004253 Free article.

2

Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition.

McCabe N, Turner NC, Lord CJ, Kluzek K, Bialkowska A, Swift S, Giavara S, O'Connor MJ, Tutt AN, Zdzienicka MZ, Smith GC, Ashworth A. McCabe N, et al. Among authors: lord cj. Cancer Res. 2006 Aug 15;66(16):8109-15. doi: 10.1158/0008-5472.CAN-06-0140. Cancer Res. 2006. PMID: 16912188

3

DNA repair deficiency as a therapeutic target in cancer.

Martin SA, Lord CJ, Ashworth A. Martin SA, et al. Among authors: lord cj. Curr Opin Genet Dev. 2008 Feb;18(1):80-6. doi: 10.1016/j.gde.2008.01.016. Epub 2008 Mar 14. Curr Opin Genet Dev. 2008. PMID: 18343102 Review.

4

Targeted therapy for cancer using PARP inhibitors.

Lord CJ, Ashworth A. Lord CJ, et al. Curr Opin Pharmacol. 2008 Aug;8(4):363-9. doi: 10.1016/j.coph.2008.06.016. Curr Opin Pharmacol. 2008. PMID: 18644251 Review.

5

A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity.

Lord CJ, McDonald S, Swift S, Turner NC, Ashworth A. Lord CJ, et al. DNA Repair (Amst). 2008 Dec 1;7(12):2010-9. doi: 10.1016/j.dnarep.2008.08.014. Epub 2008 Oct 15. DNA Repair (Amst). 2008. PMID: 18832051

6

Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors.

Mendes-Pereira AM, Martin SA, Brough R, McCarthy A, Taylor JR, Kim JS, Waldman T, Lord CJ, Ashworth A. Mendes-Pereira AM, et al. Among authors: lord cj. EMBO Mol Med. 2009 Sep;1(6-7):315-22. doi: 10.1002/emmm.200900041. EMBO Mol Med. 2009. PMID: 20049735 Free PMC article.

7

PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors.

Dedes KJ, Wetterskog D, Mendes-Pereira AM, Natrajan R, Lambros MB, Geyer FC, Vatcheva R, Savage K, Mackay A, Lord CJ, Ashworth A, Reis-Filho JS. Dedes KJ, et al. Among authors: lord cj. Sci Transl Med. 2010 Oct 13;2(53):53ra75. doi: 10.1126/scitranslmed.3001538. Sci Transl Med. 2010. PMID: 20944090

8

Rethinking ovarian cancer: recommendations for improving outcomes.

Vaughan S, Coward JI, Bast RC Jr, Berchuck A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R, Etemadmoghadam D, Friedlander M, Gabra H, Kaye SB, Lord CJ, Lengyel E, Levine DA, McNeish IA, Menon U, Mills GB, Nephew KP, Oza AM, Sood AK, Stronach EA, Walczak H, Bowtell DD, Balkwill FR. Vaughan S, et al. Among authors: lord cj. Nat Rev Cancer. 2011 Sep 23;11(10):719-25. doi: 10.1038/nrc3144. Nat Rev Cancer. 2011. PMID: 21941283 Free PMC article.

9

The promise of combining inhibition of PI3K and PARP as cancer therapy.

Rehman FL, Lord CJ, Ashworth A. Rehman FL, et al. Among authors: lord cj. Cancer Discov. 2012 Nov;2(11):982-4. doi: 10.1158/2159-8290.CD-12-0433. Cancer Discov. 2012. PMID: 23148373

10

Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor.

Barber LJ, Sandhu S, Chen L, Campbell J, Kozarewa I, Fenwick K, Assiotis I, Rodrigues DN, Reis Filho JS, Moreno V, Mateo J, Molife LR, De Bono J, Kaye S, Lord CJ, Ashworth A. Barber LJ, et al. Among authors: lord cj. J Pathol. 2013 Feb;229(3):422-9. doi: 10.1002/path.4140. J Pathol. 2013. PMID: 23165508

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

249 results

Search Page